Patient Square Capital LP Acquires New Shares in Arvinas, Inc. (NASDAQ:ARVN)

Patient Square Capital LP acquired a new position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 86,627 shares of the company's stock, valued at approximately $1,661,000. Arvinas accounts for 0.6% of Patient Square Capital LP's investment portfolio, making the stock its 18th biggest holding. Patient Square Capital LP owned 0.13% of Arvinas at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ARVN. Invesco Ltd. boosted its position in Arvinas by 1.6% during the 4th quarter. Invesco Ltd. now owns 37,254 shares of the company's stock valued at $714,000 after purchasing an additional 581 shares during the period. Rhumbline Advisers grew its holdings in shares of Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company's stock valued at $1,685,000 after buying an additional 754 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Arvinas by 0.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company's stock worth $2,694,000 after buying an additional 777 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Arvinas by 2.7% during the 4th quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock worth $755,000 after purchasing an additional 1,044 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after purchasing an additional 1,255 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ARVN. Morgan Stanley decreased their target price on shares of Arvinas from $12.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. UBS Group cut their price target on shares of Arvinas from $74.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday. The Goldman Sachs Group decreased their target price on shares of Arvinas from $12.00 to $8.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Truist Financial reiterated a "hold" rating and set a $11.00 target price (down from $21.00) on shares of Arvinas in a research report on Monday, May 5th. Finally, Wells Fargo & Company dropped their price objective on shares of Arvinas from $26.00 to $19.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $20.92.

Arvinas Stock Down 0.7%

ARVN stock traded down $0.05 on Monday, reaching $6.45. 668,498 shares of the company's stock were exchanged, compared to its average volume of 1,323,775. The firm has a market cap of $470.43 million, a PE ratio of -2.32 and a beta of 2.21. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $37.38. The stock has a fifty day moving average of $7.69 and a 200-day moving average of $15.96.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $1.14 EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the business posted ($0.97) EPS. The company's revenue for the quarter was up 646.2% on a year-over-year basis. On average, equities research analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling at Arvinas

In related news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares of the company's stock, valued at approximately $2,658,911.91. This trade represents a 5.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John G. Houston sold 31,338 shares of the business's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. This represents a 2.64% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,230 shares of company stock valued at $769,402 in the last quarter. Corporate insiders own 4.73% of the company's stock.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.